Sistema de Salut de Catalunya
Institut Català de la Salut
[Prosperini L] MS Centre, Department of Neurosciences, S. Camillo-Forlanini Hospital, Rome, Italy. [Arrambide G] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Celius EG] Department of Neurology, Oslo University Hospital, Oslo, Norway. Institute of Clinical Medicine, University of Oslo, Norway. [Goletti D] Translational Research Unit, National Institute for Infectious Diseases “Lazzaro Spallanzani”, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy. [Killestein J] Department of Neurology, Amsterdam University Medical Centers, Amsterdam, the Netherlands. [Kos D] National Multiple Sclerosis Center, Melsbroek, Belgium. KU Leuven, Department of Rehabilitation Sciences, Leuven, Belgium
Vall d'Hebron Barcelona Hospital Campus
2025-02-14T08:58:14Z
2025-02-14T08:58:14Z
2024-09
COVID-19; Multiple sclerosis; SARS-CoV-2
COVID-19; Esclerosis múltiple; SARS-CoV-2
COVID-19; Esclerosi múltiple; SARS-CoV-2
During the COVID-19 pandemic, people with multiple sclerosis (MS) and their healthcare providers have faced unique challenges related to the interaction between SARS-CoV-2, underlying neurological disease and the use of disease-modifying treatments (DMTs). Key concerns arose, primarily related to the possibility that SARS-CoV-2 infection could trigger the initial demyelinating event or exacerbate disease activity. Another major concern was the safety and efficacy of the COVID-19 vaccines, especially for patients undergoing specific treatments that could weaken their antibody responses. In the post-infection phase, identifying long COVID in patients with MS has been complicated due to the large overlap between post-infection sequelae and MS symptoms. In addition, disruptions in health and rehabilitation services have made it difficult for MS patients to access care. This Series article explores current evidence on the interaction between MS and SARS-CoV-2, identifies the challenges posed by the COVID-19 pandemic in the care of patients with MS, and discusses the significant adoption of digital health solutions, including telemedicine and new technology-based rehabilitation approaches. Based on lessons learned, recommendations and future directions are offered for managing patients with MS, rethinking healthcare systems and improving health outcomes in the post-COVID-19 pandemic era.
Article
Published version
English
Pandèmia de COVID-19, 2020-; Esclerosi múltiple - Tractament; COVID-19 (Malaltia) - Prevenció; HEALTH CARE::Environment and Public Health::Public Health::Disease Outbreaks::Epidemics::Pandemics; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; Other subheadings::Other subheadings::Other subheadings::/prevention & control; DISEASES::Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis; Other subheadings::Other subheadings::/therapy; ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::brotes de enfermedades::epidemias::pandemias; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple; Otros calificadores::Otros calificadores::/terapia
Elsevier
The Lancet Regional Health - Europe;44
https://doi.org/10.1016/j.lanepe.2024.100979
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
